XPO1 and acute myeloid leukemia: Taken together, these observations suggest that the molecular mechanisms responsible for the contribution of Exportin 1 in leukemogenesis and the effect of Exportin 1 inhibition will vary between patients due to the biological heterogeneity of the AML cell biology between patients.